How the mTOR field is put together
A pathway map shows how the molecules fit together. This section is the other half: the order in which people found out, who taught whom, and what nobody has answered yet.
46 years from the soil sample to the clinic · 5 of 30 studies on that path done in humans · 0 with an ageing endpoint.
- 01 The story in six moments6 moments · 1975–2021 Start here. From a soil sample on a Pacific island to a large trial that missed its primary endpoint, told in six short scenes.
- 02 Timelineinteractive · 6 branches The whole field as one map: each landmark study, what it made possible, and the long stretches where nothing moved. human study other
- 03 All 30 milestones1975–2021 The same studies written out in order: what each one unlocked, what it left open, and which earlier work it built on. 1970s: 1, 1990s: 3, 2000s: 15, 2010s: 10, 2020s: 1
- 04 What the field doesn't know4 open ends · 10 gaps Where the timeline stops because nobody has run the experiment, and where the Atlas itself is missing a link. “mTORC1-only, in humans?”
- 05 Lab lineage180 scientists · 153 training links Who trained in whose lab and what they took into their own. 8 large
lab families cover 74 of the 180 people.
Lab families: Snyder–Sabatini lineage · Cantley lineage · Herskowitz–Hall lineage · Teleman–Demetriades lineage · Erikson–Blenis lineage · Thompson lineage · Thomas lineage · Dixon–Guan lineage
- 06 Drug pipeline8 programmes · 7 registered trials Where the field is heading: selective mTORC1 inhibitors and rapalogs in development, why each one exists, and the programmes that stopped. Every status line is sourced and dated. Preclinical: 2, Phase 1: 2, Phase 2: 3, Phase 3: 1, stopped: 2 Checked 2026-10-18 · 2 stopped
Where the field meets next
GSA 2026 Annual Scientific Meeting (Gerontological Society of America)
Was this page useful?
Thank you. Your answer was counted anonymously.